Elon Musks Critique of The Boys Finale Reignites Debate on Media Messaging and Public Influence Novartis Upgrades FullYear Outlook Raises Sales and Profit Guidance Singapore Telecom Turmoil SimbaM1 Deal Collapse and Singtel Share Slide Highlight Sector Challenges Bernstein Initiates Coverage of Neurocrine Biosciences With Outperform Rating 221 Target Nifty 50 Could Reach 2800030000 by FY27End Smallcase Managers Suggest Despite YeartoDate Decline Inflation Rate Projected to Hit 6 in Second Quarter Top Economic Forecasters Say Core Main Inc CNM Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency RAIL Q1 2026 Earnings EPS Misses Estimates as Loss Widens Stock Inches Higher ERAS Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Climbs EMA Q1 2026 Earnings EPS Beats Estimates by 185 Shares Edge Lower LANDO Q1 2026 Earnings Preferred Stock Stays Steady With Slight EPS Beat USAS Q1 2026 Earnings EPS Misses Estimates Stock Rises Despite Negative Surprise Akso Health Group AHG Climbs 132 Navigating Support and Resistance Levels Imperial Petroleum Preferred Shares IMPPP Edge Higher Amid Steady Yield Appeal SLB Limited SLB Rallies 122 as Oil Services Stock Holds Above Key Support Jupiter Neurosciences JUNS Stages a Sharp Rebound from Support Testing Key Resistance Establishment Labs ESTA Posts Modest Gain as Shares Hold Above Key Support CISS Q3 2025 Earnings Negative EPS and Significant Stock Decline TransAct Technologies TACT Q1 2026 Earnings Surprise Profitability as EPS Beats Estimates by Wide Margin Seaport Entertainment Group Q1 2026 Earnings EPS Misses Estimates Amid Operational Development UAA Q1 2026 Earnings EPS Misses Estimates as Restructuring Costs Weigh on Results STNE Q1 2026 Earnings EPS Misses Estimates Amidst Operational Progress Stock Declines Slightly MSCI Inc MSCI Q1 2026 Earnings Narrow EPS Beat Reflects Stability in Index Analytics Americans Raid Emergency Savings to Cover Rising Gas Costs A Growing Financial Strain PWR Q1 2026 Earnings Strong EPS Beat of 287 Lifts Investor Sentiment Vistagen Therapeutics VTGN Approaches Key Support After Marginal Decline